Literature DB >> 3261754

IL-6/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells.

M Okada1, M Kitahara, S Kishimoto, T Matsuda, T Hirano, T Kishimoto.   

Abstract

rIL-6/B cell stimulatory factor 2 was found to augment CTL generation from mature as well as immature human T cells stimulated with UV-treated allogeneic cells. rIL-6 also acted on peanut agglutinin-positive murine thymocytes and Lyt-2-positive splenic T cells to give rise to CTL. rIL-6 alone could not induce CTL generation, the presence of IL-2 during the early phase of culture period was found to be essential for the IL-6 activity in the induction of CTL. The effect of rIL-6 was not mediated by the induction of IL-2 inasmuch as rIL-6 did not augment IL-2 production in MLC and anti-IL-2 antibody could not neutralize IL-6 activity. rIL-6 augmented CTL generation even when added 72 h after the initiation of cultures. The enhancing activity of rIL-6 could be neutralized with anti-IL-6 antibodies even when added 72 h after the initiation of cultures. The present data indicate that IL-6 acts in the late phase of CTL generation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3261754

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  97 in total

1.  Renal cytokine responses in acute Escherichia coli pyelonephritis in IL-6-deficient mice.

Authors:  A Khalil; K Tullus; T Bartfai; M Bakhiet; G Jaremko; A Brauner
Journal:  Clin Exp Immunol       Date:  2000-11       Impact factor: 4.330

2.  IL-6 enhances the generation of cytolytic T lymphocytes in the allogeneic mixed leucocyte reaction.

Authors:  J E Ming; R M Steinman; A Granelli-Piperno
Journal:  Clin Exp Immunol       Date:  1992-07       Impact factor: 4.330

3.  Interleukin-6 is antiproliferative to a mouse hybridoma cell line and promotive for its antibody productivity.

Authors:  F Makishima; S Terada; T Mikami; E Suzuki
Journal:  Cytotechnology       Date:  1992       Impact factor: 2.058

Review 4.  Pharmacodynamic monitoring of cyclosporin.

Authors:  W M Awni
Journal:  Clin Pharmacokinet       Date:  1992-12       Impact factor: 6.447

5.  Subpopulations of mononuclear leukocytes associated with inhibition of Ehrlich ascites tumor growth by treatment with Bothrops jararaca venom.

Authors:  Mariana Morena de Vieira Santos; Reinaldo José da Silva; Márcia Guimarães da Silva; Denise Fecchio
Journal:  Mediators Inflamm       Date:  2004-02       Impact factor: 4.711

6.  A critical role of the transcription factor fli-1 in murine lupus development by regulation of interleukin-6 expression.

Authors:  Shuzo Sato; Mara Lennard Richard; Danielle Brandon; Joy N Jones Buie; Jim C Oates; Gary S Gilkeson; Xian K Zhang
Journal:  Arthritis Rheumatol       Date:  2014-12       Impact factor: 10.995

Review 7.  Interleukin-6 and the acute phase response.

Authors:  P C Heinrich; J V Castell; T Andus
Journal:  Biochem J       Date:  1990-02-01       Impact factor: 3.857

8.  Exacerbation of chronic active Epstein-Barr virus infection in a patient with rheumatoid arthritis receiving humanised anti-interleukin-6 receptor monoclonal antibody.

Authors:  J Ogawa; M Harigai; T Akashi; K Nagasaka; F Suzuki; S Tominaga; N Miyasaka
Journal:  Ann Rheum Dis       Date:  2006-12       Impact factor: 19.103

Review 9.  Interleukin-6 blockade in ocular inflammatory diseases.

Authors:  M Mesquida; A Leszczynska; V Llorenç; A Adán
Journal:  Clin Exp Immunol       Date:  2014-06       Impact factor: 4.330

10.  Requirements for activation of CD8+ murine T cells. I. Development of cytolytic activity.

Authors:  D C Cronin; D W Lancki; F W Fitch
Journal:  Immunol Res       Date:  1994       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.